Clinical trial
Kisspeptin Influence on Glucose Homeostasis
Name
2016P001769
Description
The goal of this study is to learn about how a naturally occurring hormone called kisspeptin affects blood sugar and insulin levels.
Trial arms
Trial start
2017-07-18
Estimated PCD
2024-08-01
Trial end
2024-08-01
Status
Recruiting
Phase
Early phase I
Treatment
kisspeptin 112-121
Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
Arms:
Kisspeptin and Insulin Resistance Test
Other names:
metastin 45-54
Insulin Resistance Test
Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
Arms:
Kisspeptin and Insulin Resistance Test, Placebo and Insulin Resistance Test
Placebo
Receive IV fluids for up to 16 hours that do not contain any study drug
Arms:
Placebo and Insulin Resistance Test
Size
413
Primary endpoint
Average difference in area under the curve of insulin in response to a mixed meal tolerance test
4 hours
Eligibility criteria
Inclusion/Exclusion Criteria:
History:
* normal pubertal development
* stable weight for previous three months
* no active illicit drug use,
* no history of a medication reaction requiring emergency medical care,
* no difficulty with blood draws.
Physical examination:
• systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg,
Laboratory studies: (per MGH reference ranges)
* normal hemoglobin, unless hypogonadal then no lower than 0.5 gm/dL below the lower limit of the reference range for normal women (as men and women with hypogonadism have lower hemoglobin levels off of treatment)
* hemoglobin A1C \< 6.5%
* BUN, creatinine not elevated
* AST, ALT \< 3x upper limit of normal
* negative serum pregnancy test (for all women)
* no hyperlipidemia by fasting lipid panel
Additional Criteria by Study Population
Healthy Men:
* normal body mass index (BMI between 18.5-25)
* no history of chronic disease, except well controlled thyroid disease
* no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable.
* no history of diabetes in a first degree relative.
Healthy Women:
* normal body mass index (BMI between 18.5-25)
* no history of chronic disease, except well controlled thyroid disease,
* no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine or seasonal allergy medications is acceptable.
* no history of diabetes in a first degree relative,
* no use of contraceptive pills, patches or vaginal rings within last 4 weeks.
* regular menstrual cycles
Postmenopausal Women:
* body mass index (BMI between 18.5-30)
* no history of chronic disease except thyroid disease, and osteoporosis,
* no recent use of prescription medications which interfere with metabolism or reproduction. Use of levothyroxine, osteoporosis medications or seasonal allergy medications is acceptable,
* no history of diabetes in a first degree relative,
* normal activate protein C resistance screen,
* if applicable, able to undergo appropriate washout from hormone therapy.
Men and Women with Impaired Glucose Tolerance (IGT):
* diagnosis of impaired glucose tolerance by oral glucose tolerance test,
* all medical conditions well-controlled.
Men and Women with Hypogonadism
* diagnosis of hypogonadism,
* all other medical conditions well-controlled,
* if applicable, able to undergo appropriate washout from hormone therapy.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 413, 'type': 'ESTIMATED'}}
Updated at
2023-07-19
1 organization
1 product
2 indications
Organization
Stephanie B. SeminaraProduct
KisspeptinIndication
Impaired Glucose ToleranceIndication
Hypogonadism